Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

The ENHANCE Study: taVNS and Psilocybin

NCT: NCT05866471 · RECRUITING

NCT IDNCT05866471
StatusRECRUITING
Start Date2025-01-27
Completion2028-01

Brief Summary

This study will examine whether combining a single dose of psilocybin with non-invasive transcutaneous auricular vagus nerve stimulation (taVNS), a potential inducer of neuroplasticity and enhanced memory formation, will enhance the long-term beneficial behavioral effects of psilocybin when compared to sham taVNS or no VNS by allowing memory for insights gained during the psychedelic experience to remain vivid after they will have faded in subjects who receive psilocybin followed by sham taVNS or no VNS.

Frequently Asked Questions

What is The ENHANCE Study: taVNS and Psilocybin?

The ENHANCE Study: taVNS and Psilocybin is a clinical trial registered under NCT05866471. Current status: RECRUITING.

What is the status of NCT05866471?

The current status of NCT05866471 (The ENHANCE Study: taVNS and Psilocybin) is: RECRUITING.

When did The ENHANCE Study: taVNS and Psilocybin start?

The ENHANCE Study: taVNS and Psilocybin started on 2025-01-27.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.